A clinician's paradigm in the treatment of atopic dermatitis

Journal of the American Academy of Dermatology

Volumn 53, Issue 1 SUPPL., 2005, Pages

  Abramovits, William ^a,b,c  

^a Texas Dermatology Associates PA   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CERAMIDE DERIVATIVE; CLOBETASOL PROPIONATE; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOSPORIN; DOXEPIN; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INFLIXIMAB; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PIMECROLIMUS; PSEUDOMONIC ACID; PSORALEN; RECOMBINANT GAMMA INTERFERON; TACROLIMUS; TAR; ZILEUTON;

ALGORITHM; ANTIBODY TITER; ARTHRALGIA; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BONE MARROW TOXICITY; CANCER; CARCINOGENICITY; CELL COUNT; CHILL; CLEARANCE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENCY; EOSINOPHIL; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER TOXICITY; MAINTENANCE THERAPY; MELANOMA; MONOTHERAPY; MYALGIA; NONHODGKIN LYMPHOMA; PANCREATITIS; PRIORITY JOURNAL; PROPHYLAXIS; PUVA; RIGOR; SIDE EFFECT; SKIN CANCER; SKIN FUNCTION; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT INDICATION; TREATMENT PLANNING; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ALGORITHMS; ANTI-INFLAMMATORY AGENTS; CALCINEURIN; CASE MANAGEMENT; COMBINED MODALITY THERAPY; DERMATITIS, ATOPIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; PUVA THERAPY; SKIN DISEASES, INFECTIOUS; ULTRAVIOLET THERAPY;

EID: 20444456996     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.04.032     Document Type: Article

References (95)

1. D.Y.M. Leung, J.M. Hanifin, and E.N. Charlesworth Disease management of atopic dermatitis: a practice parameter Ann Allergy Asthma Immunol 79 1997 197 211
2. W. Abramovits, A.M. Goldstein, and L.C. Stevenson Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis Clin Dermatol 21 2003 383 391
3. S.M. Jones Triggers of atopic dermatitis Immunol Allergy Clin North Am 22 2002 55 72
4. G. Imokawa Lipid abnormalities in atopic dermatitis J Am Acad Dermatol 45 Suppl 2001 S29 S32
5. D.Y.M. Leung, and T. Bieber Atopic dermatitis Lancet 361 2003 151 160
6. S.L. Chamlin, J. Kao, I.J. Frieden, M.Y. Sheu, A.J. Fowler, and J.W. Fluhr Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity J Am Acad Dermatol 47 2002 198 208
7. Shapiro SD. Efficacy of a next-generation, lipid-balanced skin repair cream for dry skin and inflammatory dermatosis. Paper presented at the 62nd Annual Meeting of the American Academy of Dermatology, Washington, DC, Feb 6-11, 2004 Washington, DC [abstract P166].
8. A.M. Goldstein, and W. Abramovits Ceramides and the stratum corneum: structure, function, and new methods to promote repair Int J Dermatol 42 2003 256 259
9. J.M. Hanifin, K.D. Cooper, V.C. Ho, S. Kang, B.R. Krafchik, and D.J. Margolis Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines" J Am Acad Dermatol 50 2004 391 404
10. S. Kang, A.W. Lucky, D. Pariser, I. Lawrence, and J.M. Hanifin Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children J Am Acad Dermatol 44 Suppl 2001 S58 S64
11. S.M. Rikkers, G.N. Holland, G.E. Drayton, F.K. Michel, M.F. Torres, and S. Takahashi Topical tacrolimus treatment of atopic eyelid disease Am J Ophthalamol 135 2003 297 302
12. L.M. Gianni, and M.M. Sulli Topical tacrolimus in the treatment of atopic dermatitis Ann Pharmacother 35 2001 943 946
13. R.A. Graham-Brown, and M. Grassberger Pimecrolimus: a review of pre-clinical and clinical data Int J Clin Pract 57 2003 319 327
14. V.C. Ho, A. Gupta, R. Kaufmann, G. Todd, F. Vanaclocha, and R. Takaoka Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants J Pediatr 142 2003 155 162
15. Protopic [package insert] 2002 Fujisawa Healthcare Deerfield (IL)
16. Elidel [package insert] 2003 Novartis Pharmaceuticals East Hanover (NJ)
17. S. Kempers, M. Boguniewicz, E. Carter, M. Jarratt, D. Pariser, and D. Stewart A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis J Am Acad Dermatol 51 2004 515 525
18. I. Lawrence Three studies in pediatric and adult patients demonstrate that tacrolimus ointment is safe and effective in the treatment of atopic dermatitis Acta Dermatovenerol Croat 11 2003 126 127
19. Koo J, Fleischer AB Jr, Abramovits W. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis. Results in 8,000 patients. (manuscript submitted).
20. A. Paller, M. Lebwohl, A.B. Fleischer Jr., R. Antaya, R.G. Langley, and R.S. Kirsner Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized comparative studies J Am Acad Dermatol 52 2005 810 822
21. G.P. Thami, and R. Sarkar Coal tar: past, present and future Clin Exp Dermatol 27 2002 99 103
22. T. Langeland, H.E. Fagertun, and S. Larsen Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis: a multi-crossover-designed study Allergy 49 1994 22 26
23. J. Berth-Jones, and R.A. Graham-Brown Failure of terfenadine in relieving the pruritus of atopic dermatitis Br J Dermatol 121 1989 635 637
24. V. Doherty, D.G. Sylvester, C.T. Kennedy, S.G. Harvey, J.G. Calthrop, and J.R. Gibson Treatment of itching in atopic eczema with antihistamines with a low sedative profile BMJ 298 1989 96
25. L. Krause, and S. Shuster Mechanism of action of antipruritic drugs Br Med J 287 1983 1199 1200
26. M. Hannuksela, K. Kalimo, K. Lammintausta, T. Mattila, K. Turjanmaa, and E. Varjonen Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults Ann Allergy 70 1993 127 133
27. S. Knowles Atopic dermatitis Pharm Pract July 2002 1 8
28. J.M. Naeyaert, J.M. Lachapelle, H. Degreef, M. de la Brassinne, M. Heene, and J. Lambert Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus Dermatology 198 1999 145 152
29. J.I. Harper, I. Ahmed, G. Barclay, M. Lacour, P. Hoeger, and M.J. Cork Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy Br J Dermatol 142 2000 52 58
30. H. Granlund, P. Erkko, M. Sinisalo, and S. Reitamo Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy Br J Dermatol 132 1995 106 112
31. M. Grundmann-Kollmann, M. Podda, F. Ochsendorf, W.H. Boehncke, R. Kaufmann, and T.M. Zollner Mycophenolate mofetil is effective in the treatment of atopic dermatitis Arch Dermatol 137 2001 870 873
32. K. Neuber, I. Schwartz, G. Itschert, and A.T. Dieck Treatment of atopic eczema with oral mycophenolate mofetil Br J Dermatol 143 2000 385 391
33. J. Berth-Jones, A. Takwale, E. Tan, G. Barclay, S. Agarwal, and I. Ahmed Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial Br J Dermatol 147 2002 324 330
34. D.A. Buckley, P. Baldwin, and S. Rogers The use of azathioprine in severe adult atopic eczema J Eur Acad Dermatol Venereol 11 1998 137 140
35. L. Scerri Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses Adv Exp Med Biol 455 1999 343 348
36. L.A. Murphy, and D. Atherton A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression Br J Dermatol 147 2002 308 315
37. J.T. Lear, J.S. English, P. Jones, and A.G. Smith Retrospective review of the use of azathioprine in severe atopic dermatitis J Am Acad Dermatol 35 1996 642 643
38. S.J. Meggitt, and N.J. Reynolds Azathioprine for atopic dermatitis Clin Exp Dermatol 26 2001 369 375
39. L.C. Schneider, Z. Baz, C. Zarcone, and D. Zurakowski Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis Ann Allergy Asthma Immunol 80 1998 263 268
40. J. Musial, M. Milewski, A. Undas, P. Koplinski, M. Duplaga, and A. Szczeklik Interferon-gamma in the treatment of atopic dermatitis: influence on T-cell activation Allergy 50 1995 520 523
41. U. Reinhold, S. Kukel, J. Brzoska, and H.W. Kreysel Systemic interferon gamma treatment in severe atopic dermatitis J Am Acad Dermatol 29 1993 58 63
42. J.M. Hanifin, L.C. Schneider, D.Y.M. Leung, C.N. Ellis, H.S. Jaffe, and A.E. Izu Recombinant interferon gamma therapy for atopic dermatitis J Am Acad Dermatol 28 1993 189 197
43. S.R. Stevens, J.M. Hanifin, T. Hamilton, S.J. Tofte, and K.D. Cooper Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels Arch Dermatol 134 1998 799 804
44. I.G. Jang, J.K. Yang, H.J. Lee, J.K. Yi, H.O. Kim, and C.W. Kim Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma J Am Acad Dermatol 42 2000 1033 1040
45. A.Y. Pei, H.H. Chan, and T.F. Leung Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study Pediatr Allergy Immunol 12 2001 154 158
46. G.L. Capella, E. Grigerio, and G. Altomare A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults Eur J Dermatol 11 2001 209 213
47. D.J. Yanase, and K. David-Bajar The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis J Am Acad Dermatol 44 2001 89 93
48. D.P. Woodmansee, and R.A. Simon A pilot study examining the role of zileuton in atopic dermatitis Ann Allergy Asthma Immunol 83 1999 548 552
49. G. D'Amato, V. Oldani, and C.F. Donner Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases Monaldi Arch Chest Dis 59 2003 25 29
50. S. Jolles A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis Clin Exp Dermatol 27 2002 3 7
51. J.E. Leyden, R.R. Marples, and A.M. Kligman Staphylococcus aureus in the lesions of atopic dermatitis Br J Dermatol 90 1974 525 530
52. R. Lever, K. Hadley, D. Downey, and R. Mackie Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy Br J Dermatol 119 1988 189 198
53. D.L. Bratton, K.R. May, J.M. Kailey, D.E. Doherty, and D.Y. Leung Staphylococcal toxic shock syndrome toxin-1 inhibits monocyte apoptosis J Allergy Clin Immunol 103 1999 895 900
54. D.Y.M. Leung, R. Harbeck, P. Bina, R.F. Reiser, E. Yang, and D.A. Norris Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis: evidence for a new group of allergens J Clin Invest 92 1993 1374 1380
55. L. Skov, J.V. Olsen, R. Giorno, P.M. Schlievert, O. Baadsgaard, and D.Y.M. Leung Application of staphylococcal enterotoxin B on normal and atopic cells induces up-regulation of T cells by a superantigen-mediated mechanism J Allergy Clin Immunol 105 2000 820 826
56. M.F. Hofer, R.J. Harbeck, P.M. Schlievert, and D.Y.M. Leung Staphylococcus toxins augment specific IgE responses by atopic patients exposed to allergen J Invest Dermatol 112 1999 171 176
57. D. Abeck, and M. Mempel Staphylococcal aureus colonization in atopic dermatitis and its therapeutic implications Br J Dermatol 139 1998 13 16
58. J.C.M. Giménez Atopic dermatitis Allergol Immunol Clin 15 2000 279 295
59. N.J. Reynolds, V. Franklin, J.C. Gray, B.L. Diffey, and P.M. Farr Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomized controlled trial Lancet 357 2001 2012 2016
60. S.A. George, D.J. Bilsland, B.E. Johnson, and J. Ferguson Narrow-band (TL-10) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis Br J Dermatol 128 1993 49 56
61. M. Grundmann-Kollmann, S. Behrens, M. Podda, R.U. Peter, R. Kaufmann, and M. Kerscher Phototherapy for atopic eczema with narrow-band UVB J Am Acad Dermatol 40 1999 995 997
62. J. Krutmann, T.L. Diepgen, T.A. Luger, S. Grabbe, H. Meffert, and N. Sonnichsen High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial J Am Acad Dermatol 38 1998 589 593
63. D. Abeck, T. Schmidt, H. Fesq, K. Strom, M. Mempel, and K. Brockow Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis J Am Acad Dermatol 42 2000 254 257
64. S. Tzaneva, A. Seeber, M. Schwaiger, H. Honigsmann, and A. Tanew High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis J Am Acad Dermatol 45 2001 503 507
65. J. Jekler, and O. Larko UVA solarium versus UVB phototherapy of atopic dermatitis: a paired-comparison study Br J Dermatol 125 1991 569 572
66. A.D. Morris, and E.M. Saihan Maintenance psoralen plus ultraviolet A therapy: does it have a role in the treatment of severe atopic eczema? Br J Dermatol 146 2002 705 707
67. R.S. Stern, L.A. Thibodeau, R.A. Kleinermann, J.A. Parrish, and T.B. Fitzpatrick Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis N Engl J Med 300 1979 809 813
68. R.S. Stern, and R. Lange Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment J Invest Dermatol 91 1988 120 124
69. T. Henseler, E. Christophers, H. Honigsmann, and K. Wolff Skin tumors in the European PUVA study J Am Acad Dermatol 16 1987 108 116
70. R.S. Stern The risk of melanoma in association with long-term exposure to PUVA J Am Acad Dermatol 44 2001 755 761
71. J.J. Leyden, and A.M. Kligman The case for steroid-antibiotic combinations Br J Dermatol 96 1977 179 187
72. P.F. Ainley-Walker, L. Patel, and T.J. David Side to side comparison of topical treatment in atopic dermatitis Arch Dis Child 79 1998 149 152
73. T.S. Housman, B.G. Mellen, S.R. Rapp, A.B. Fleischer Jr., and S.R. Feldman Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference Cutis 70 2002 327 332
74. A.B. Gottlieb, R. Ford, and M.C. Spellman The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions J Cutan Med Surg 7 2003 185 192
75. Y.A. George, S.M. Ravis, and J. Gottlieb Betamethasone valerate 0.12% in foam vehicle for scalp seborrheic dermatitis in African Americans Cosmet Dermatol 15 2002 23 27
76. L.F. Stein, A. Sherr, G. Solodkina, A.B. Gottlieb, and U. Chaudhari Betamethasone valerate foam for treatment of nonscalp psoriasis J Cutan Med Surg 5 2001 303 307
77. M. Lebwohl, D. Sherer, K. Washenik, G.G. Krueger, A. Menter, and J. Koo A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis Int J Dermatol 41 2002 269 274
78. T.J. Franz, D.A. Parsell, J.A. Myers, and J.F. Hannigan Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery Int J Dermatol 39 2000 535 538
79. T.J. Franz, D.A. Parsell, R.M. Halualani, J.F. Hannigan, J.P. Kalbach, and W.S. Harkonen Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy Int J Dermatol 38 1999 628 632
80. S.R. Feldman, S.M. Ravis, A.B. Fleischer Jr., A. McMichael, E. Jones, and R. Kaplan Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis J Cutan Med Surg 5 2001 386 389
81. L. Andreassi, A. Giannetti, and M. Milani Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients Br J Dermatol 148 2003 134 138
82. Tanojo H, Lenn J, Sykes J, Kalashnikova L, Huang X. Effects of co-application on the in vitro skin penetration and drug distribution of betamethasone 17-valerate and tacrolimus. Poster presented at the 61st Annual Meeting of the American Academy of Dermatology, San Francisco, Calif, 2003.
83. H.M. Torok, R. Maas-Irslinger, and R.M. Slayton Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis Cutis 72 2003 161 166
84. Physicians' desk reference 56th ed. 2002 Medical Economics Montvale (NJ)
85. U. Wahn, J.D. Bos, M. Goodfield, R. Caputo, K. Papp, and A. Manjra Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children Pediatrics 110 2002 e2
86. H. Kyllonen, A. Remitz, J.M. Mandelin, P. Elg, and S. Reitamo Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis Br J Dermatol 150 2004 1174 1181
87. T.A. Luger, M. Lahfa, R. Folster-Holst, W.P. Gulliver, R. Allen, and S. Molloy Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis J Dermatolog Treat 15 2004 169 178
88. M. Meurer, M. Fartasch, G. Albrecht, T. Vogt, M. Worm, and T. Ruzicka Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis Dermatology 208 2004 365 372
89. J.D. Bos Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis Eur J Dermatol 13 2003 455 461
90. A. Kapp, K. Papp, A. Bingham, R. Folster-Holst, J.P. Ortonne, and P.C. Potter Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug J Allergy Clin Immunol 110 2002 277 284
91. M. Meurer, R. Folster-Holst, G. Wozel, G. Weidinger, M. Junger, and M. Brautigam Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study Dermatology 205 2002 271 277
92. S. Reitamo, A. Wollenberg, E. Schopf, J.L. Perrot, R. Marks, and T. Ruzicka Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group Arch Dermatol 136 2000 999 1006
93. S. Reitamo, A. Remitz, H. Kyllonen, and J. Saarikko Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis Am J Clin Dermatol 3 2002 381 388
94. W. Abramovits, M. Boguniewicz, M.M. Prendergast, M. Tokar, and K.B. Tong Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis J Med Economics 6 2003 1 14
95. C.N. Ellis, L.A. Drake, M.M. Prendergast, W. Abramovits, M. Boguniewicz, and C.R. Daniel Cost of atopic dermatitis and eczema in the United States J Am Acad Dermatol 46 2002 361 370